We observed that enhanced tumor progression in the group treated with sEVs isolated form CATED‐overexpressing cells was reversed upon the administration of ERKi (Figure 8f; Figure S11b, Supporting Information), whereas CATED expression, as well as DHX36 and RAP1A levels, were significantly elevated in the CATED‐overexpressing sEV group and were not affected by ERKi (Figure S11c–e, Supporting Information). The gene discussed is RAP1A; the disease is neoplasm.